The global molecular quality control market size was valued at USD 230 million in 2025 and is projected to grow from USD 246.10 million in 2026 to USD 422.85 million by 2034, registering a CAGR of 7% during the forecast period from 2026 to 2034. North America dominated the molecular quality control market with a market share of 39.5% in 2025.
The molecular quality control market is evolving with the growing adoption of advanced diagnostics like PCR and NGS, driving demand for assay-specific, multi-analyte, and instrument-compatible control materials to ensure accuracy and regulatory compliance. The market is further fueled by the integration of multiplex and syndromic testing panels and the rise of decentralized, near-patient testing, which increases the need for versatile, stable, and user-friendly controls. However, growth is restrained by the premium pricing of advanced controls and the limited availability of standardized reference materials for rare or emerging targets. Opportunities lie in the expansion of personalized medicine and companion diagnostics, which require disease-specific, patient-matched controls, as well as the adoption of digital and cloud-connected laboratory systems, enabling real-time performance monitoring, automated quality management, and integration of data-driven workflows.
Download a Free Sample To learn more about this report,
Growing Adoption of Multi-Analyte and Third-Party Molecular Quality Controls
The molecular quality control market is increasingly shifting toward multi-analyte and independent third-party controls that can support multiple molecular assays while providing laboratories with objective verification of testing performance. These controls are becoming more valuable as laboratories manage multiplex infectious disease panels, oncology assays, genetic testing, and other complex workflows that require consistent analytical performance across instruments and reagent batches.
Increasing Integration of Automation and Digital Quality Management in Molecular Testing
Molecular laboratories are increasingly integrating automated quality control workflows with laboratory information systems and digital monitoring platforms to track assay performance, identify deviations, and maintain traceability. This shift is moving quality assurance from periodic manual checks toward continuous monitoring, allowing laboratories to analyze quality trends across instruments, locations, operators, and testing batches.
Expansion of Molecular Testing Applications Across Clinical and Research Settings Supports Market Growth
Molecular testing is expanding across infectious disease diagnostics, oncology, genetic testing, precision medicine, and research applications, increasing the complexity and diversity of laboratory workflows. The broader use of PCR, next-generation sequencing, multiplex assays, and molecular biomarker testing is strengthening the need for reliable laboratory processes and performance verification, supporting the overall molecular quality control market.
High Costs and Regulatory Requirements Can Limit Adoption of Advanced Quality Controls
Molecular quality control programs require recurring expenditure on control materials, validation procedures, proficiency testing, laboratory personnel, and documentation. Evolving regulatory requirements can further increase compliance costs as laboratories and manufacturers must demonstrate traceability, analytical performance, and consistent quality, creating greater financial pressure for smaller diagnostic facilities.
Expansion of Quality Control Solutions for Oncology and Genetic Testing Creates New Growth Opportunities
The increasing use of molecular biomarkers in oncology, hereditary disease testing, and precision medicine is creating opportunities for specialized quality control materials designed for complex genetic and molecular assays. As laboratories expand testing for targeted biomarkers and sequencing-based diagnostics, demand is increasing for controls that can verify the performance of these assays and support reliable clinical interpretation.
Maintaining Control Material Stability and Compatibility Across Complex Testing Platforms Creates Challenges
Molecular quality controls must accurately replicate relevant biological characteristics while remaining stable during storage, transportation, and repeated laboratory use. Differences among PCR, sequencing, multiplex, and other molecular platforms can also require application-specific controls, increasing development complexity and making it challenging to provide standardized materials that perform consistently across diverse diagnostic workflows.
Independent Controls Segment Dominated the Market with 68% Share in 2025
The independent controls segment dominated the global molecular quality controls market with a 68% share in 2025, representing a market value of USD 0.16 billion. The segment is projected to grow at a CAGR of 7.8% during 2026–2034. Its dominance is driven by their broad compatibility across multiple diagnostic platforms, ability to provide unbiased quality assessment, and increasing adoption in clinical laboratories for validating test accuracy and reliability. The growing emphasis on standardized quality assurance practices continues to strengthen the segment's market position.
The instrument-specific controls segment continues to witness steady demand owing to their optimized performance with specific diagnostic systems and their ability to improve testing accuracy. Increasing adoption of automated molecular diagnostic platforms and manufacturer-recommended quality control protocols continues to support the segment's growth.
Request Customizationto receive a tailored report.
Multi-analyte Controls Segment is Projected to Register the Fastest Growth at a CAGR of 8%
The multi-analyte controls segment is projected to register the fastest growth at a CAGR of 8% during 2026–2034. In 2025, the segment accounted for 46% of the global molecular quality controls market, with a value of USD 0.11 billion. Growth is driven by the increasing demand for comprehensive quality control solutions that validate multiple biomarkers within a single assay, improve laboratory efficiency, and reduce testing costs. Rising adoption of multiplex molecular diagnostics is expected to further support the segment's growth.
The single-analyte controls segment dominated the market owing to their widespread use in validating individual diagnostic targets and ensuring high testing accuracy for specific molecular assays. Their continued application in routine clinical diagnostics and regulatory quality assurance programs supports stable market demand.
Oncology Testing Segment is Projected to Register the Fastest Growth at a CAGR of 8.2%
The oncology testing segment is projected to register the fastest growth at a CAGR of 8.2% during 2026–2034. In 2025, the segment accounted for 25% of the global molecular quality controls market, with a value of USD 0.06 billion. Growth is driven by increasing adoption of precision oncology, expanding use of molecular biomarkers, and rising demand for highly accurate cancer diagnostic testing. Continuous advancements in companion diagnostics and personalized medicine are expected to further accelerate the segment's growth.
The infectious disease diagnostics segment dominated the market owing to the high volume of molecular testing performed for viral, bacterial, and other infectious diseases. Increasing emphasis on accurate diagnostic results and stringent laboratory quality standards continues to support the widespread adoption of molecular quality controls in infectious disease testing. The genetic testing segment continues to witness steady growth due to the expanding use of genomic testing for inherited disorders, prenatal screening, and personalized healthcare applications.
IVD Manufacturers & Contract Research Organizations Segment is Projected to Register the Fastest Growth at a CAGR of 7.9%
The IVD manufacturers & contract research organizations segment is projected to register the fastest growth at a CAGR of 7.9% during 2026–2034. In 2025, the segment accounted for 19% of the global molecular quality controls market, with a value of USD 0.04 billion. Growth is driven by increasing investments in diagnostic assay development, expanding clinical validation activities, and rising demand for standardized quality control materials during product development and regulatory approval processes. Growing innovation in molecular diagnostics continues to support the segment's expansion.
The diagnostic laboratories segment dominated the market owing to the high volume of molecular diagnostic testing, stringent quality assurance requirements, and increasing adoption of standardized laboratory practices. The hospitals segment continues to maintain steady demand as molecular testing becomes increasingly integrated into routine clinical care and disease management. The academic & research institutes segment remains an important contributor to the market through ongoing research activities, assay development, and advancements in molecular diagnostic technologies.
Speak to an Analystto discuss market opportunities.
North America molecular quality control market accounted for 39.5% of the global market, reaching USD 0.09 billion in 2025, and is projected to grow at a CAGR of 7.1% during the forecast period. The market is driven by increasing adoption of molecular diagnostics, rising demand for accurate laboratory testing, expanding use of quality control products in clinical laboratories, and stringent regulatory requirements. Continuous advancements in molecular testing technologies and growing investments in healthcare infrastructure continue to support regional market growth.
The US market was valued at USD 0.08 billion in 2025, making it the largest contributor in North America. Rising demand for high-quality molecular diagnostic testing, increasing adoption of automated laboratory workflows, expanding use of precision medicine, and continuous investments in laboratory quality assurance continue to drive market growth.
Canada's market reached USD 0.01 billion in 2025. Growing healthcare investments, increasing implementation of molecular diagnostic platforms, expanding laboratory accreditation programs, and rising demand for standardized quality control solutions continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe molecular quality control market accounted for 28% of the global market, reaching USD 0.06 billion in 2025, and is projected to grow at a CAGR of 7% during the forecast period. Rising demand for accurate diagnostic testing, increasing adoption of molecular assays, expanding laboratory automation, and stringent quality standards continue to strengthen regional market growth. Ongoing investments in advanced diagnostic technologies further support market expansion.
The UK market was valued at USD 0.01 billion in 2025. Increasing adoption of molecular diagnostics, expanding laboratory modernization initiatives, growing emphasis on quality assurance, and rising investments in precision diagnostics continue to support market growth.
Germany market accounted for USD 0.02 billion in 2025. Strong clinical laboratory infrastructure, increasing use of molecular testing technologies, expanding quality management systems, and continuous investments in diagnostic innovation continue to drive market expansion.
Asia Pacific molecular quality control market accounted for 22.5% of the global market, reaching USD 0.05 billion in 2025, and is projected to grow at a CAGR of 8.9% during the forecast period. Rising healthcare expenditure, expanding molecular diagnostic laboratories, increasing awareness of quality assurance, and growing demand for reliable diagnostic testing continue to accelerate regional market growth. Government support for laboratory modernization further strengthens market expansion.
Japan's market generated USD 0.01 billion in 2025. Increasing adoption of precision diagnostics, expanding laboratory automation, growing investments in healthcare innovation, and rising demand for standardized quality control solutions continue to support market growth.
China's market accounted for USD 0.02 billion in 2025, representing the largest share within Asia Pacific. Expanding molecular diagnostic capabilities, increasing healthcare investments, growing laboratory infrastructure, and rising adoption of advanced quality control products continue to drive market expansion.
Latin America molecular quality control market accounted for 6% of the global market, reaching USD 0.01 billion in 2025, and is projected to grow at a CAGR of 6.8% during the forecast period. Increasing healthcare investments, expanding molecular testing services, growing awareness of laboratory quality standards, and rising demand for reliable diagnostic solutions continue to support regional market growth.
Brazil market accounted for USD 0.01 billion in 2025. Rising adoption of molecular diagnostic technologies, expanding laboratory services, increasing healthcare modernization initiatives, and growing focus on quality assurance continue to support market expansion.
Middle East & Africa molecular quality control market accounted for 4% of the global market, totaling USD 0.01 billion in 2025, and is projected to grow at a CAGR of 6.4% during the forecast period. Increasing investments in healthcare infrastructure, expanding access to molecular diagnostics, growing laboratory quality improvement initiatives, and rising adoption of standardized testing protocols continue to support regional market growth.
The UAE market was valued at USD 0.003 billion in 2025. Increasing investments in advanced laboratory facilities, expanding molecular diagnostic services, growing healthcare digitization, and rising demand for quality assurance solutions continue to drive market growth.
Africa's market reached USD 0.007 billion in 2025. Improving laboratory infrastructure, increasing access to molecular diagnostic testing, expanding healthcare investments, and growing adoption of quality management systems continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Bovine Serum Market Size, Share, Growth, Analysis, Report, 2034
Asia Pacific TB Diagnostics Market Size, Share & Growth Graph by 2034
South Korea Epigenetics Market Size, Supply & Growth Report 2034
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
We are featured on:
sales@straitsresearch.com